Last edition
News about "liver fibrosis "
GSK's Efimosfermin Secures FDA Breakthrough and EMA PRIME Status for MASH Treatment
The dual regulatory designations from US FDA and European Medicines Agency fast-track development of GSK’s investigational liver therapy for metabolic dysfunction-associated steatohepatitis.
Liver Fibrosis | 29/04/2026 | By News Bureau
Novo Nordisk to Acquire Akero Therapeutics Alongside Promising MASH Therapy Efruxifermin
Danish pharma giant Novo Nordisk has signed a definitive agreement to acquire Akero Therapeutics, a San Francisco-based clinical-stage biopharmaceutical company focused on developing innovative therapies for serious metabolic diseases.
Liver Fibrosis | 10/10/2025 | By Dineshwori | 301
Novo Nordisk's Wegovy Approved for Treatment of MASH in Adults with Liver Fibrosis
The US FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, according to Novo Nordisk.
Liver Fibrosis | 16/08/2025 | By Dineshwori | 350
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy